Imaging appearance of treated hepatocellular carcinoma

World Journal of Hepatology

Volumn 5, Issue 8, 2013, Pages 417-424

  Agnello, Francesco ^a   Salvaggio, Giuseppe ^a   Cabibbo, Giuseppe ^a   Maida, Marcello ^a   Lagalla, Roberto ^a   Midiri, Massimo ^a   Brancatelli, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Hepatocellular carcinoma; Imaging; Treatment

Indexed keywords

EID: 84884311107     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i8.417     Document Type: Article

References (38)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
2. Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther 2013; 13: 469-479 [PMID: 23560841 DOI: 10.1586/era.13.21]
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
4. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-2063 [PMID: 21898496 DOI: 10.1002/hep.24644]
5. Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol 2013; 9: 845-854 [PMID: 23718305 DOI: 10.2217/fon.13.33]
6. Curro G, Jiao L, Scisca C, Baccarani U, Mucciardi M, Habib N, Navarra G. Radiofrequency-assisted liver resection in cirrhotic patients with hepatocellular carcinoma. J Surg Oncol 2008; 98: 407-410 [PMID: 18683211 DOI: 10.1002/jso.21129]
7. Kleinert R, Wahba R, Bangard C, Prenzel K, Hölscher AH, Stippel D. Radiomorphology of the Habib sealer-induced resection plane during long-time followup: a longitudinal single center experience after 64 radiofrequency-assisted liver resections. HPB Surg 2010; 2010: 403097 [PMID: 20862384 DOI: 10.1155/2010/403097]
8. McGahan JP, Khatri VP. Imaging findings after liver resection by using radiofrequency parenchymal coagulation devices: initial experiences. Radiology 2008; 247: 896-902 [PMID: 18487541 DOI: 10.1148/radiol.2473070949]
9. Taibbi A, Furlan A, Sandonato L, Bova V, Galia M, Marin D, Cabibbo G, Soresi M, Bartolotta TV, Midiri M, Lagalla R, Brancatelli G. Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device--initial observations. Eur J Radiol 2012; 81: 663-670 [PMID: 21306849 DOI: 10.1016/j.ejrad.2011.01.015]
10. Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013; 201: 80-96 [PMID: 23789661 DOI: 10.2214/AJR.13.10706]
11. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, Tong MJ, Amado RG, Busuttil RW. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954-960 [PMID: 15681691 DOI: 10.1148/ radiol.2343040153]
12. Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P, Roche A, Sigal R. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002; 223: 255-262 [PMID: 11930075 DOI: 10.1148/radiol.2231010780]
13. Winters SD, Jackson S, Armstrong GA, Birchall IW, Lee KH, Low G. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. Clin Radiol 2012; 67: 649-655 [PMID: 22300821 DOI: 10.1016/j.crad.2011.11.013]
14. Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2013; 58: 169-177 [PMID: 22944253 DOI: 10.1016/j.jhep.2012.08.022]
15. Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors: Part 1, Normal findings. AJR Am J Roentgenol 2013; 200: 184-193 [PMID: 23255761 DOI: 10.2214/AJR.12.8478]
16. Park Y, Choi D, Lim HK, Rhim H, Kim YS, Kim SH, Lee WJ. Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. AJR Am J Roentgenol 2008; 191: 215-220 [PMID: 18562748 DOI: 10.2214/AJR.07.3297]
17. Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors: Part 2, Abnormal findings. AJR Am J Roentgenol 2013; 200: 194-204 [PMID: 23255762 DOI: 10.2214/AJR.12.8479]
18. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43-58 [PMID: 22190656 DOI: 10.1148/radiol.11110144]
19. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524 [PMID: 19174803 DOI: 10.1038/ ajg.2008.80]
20. Oeda S, Mizuta T, Isoda H, Kuwashiro T, Iwane S, Takahashi H, Kawaguchi Y, Eguchi Y, Ozaki I, Tanaka K, Fujimoto K. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: Comparison with ethanol injection. Hepatogastroenterology 2013 May 1; Epub ahead of print [PMID: 23635508 DOI: 10.5754/hge121270]
21. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-459 [PMID: 19065676 DOI: 10.1002/hep.22648]
22. Bartolozzi C, Lencioni R, Caramella D, Mazzeo S, Ciancia EM. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging. AJR Am J Roentgenol 1994; 162: 827-831 [PMID: 8141000]
23. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20: S425-S434 [PMID: 19560030 DOI: 10.1016/j.jvir.2009.04.021]
24. Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther 2011; 34: 196-204 [PMID: 21564144 DOI: 10.1111/ j.1365-2036.2011.04694.x]
25. Kim HC, Kim AY, Han JK, Chung JW, Lee JY, Park JH, Choi BI. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002; 225: 773-780 [PMID: 12461260]
26. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 532-540 [PMID: 19847482 DOI: 10.1007/s00270-009-9728-y]
27. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrastenhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193: 1044-1052 [PMID: 19770328 DOI: 10.2214/AJR.08.1461]
28. Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N. Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 2009; 20: 30-38 [PMID: 19028117 DOI: 10.1016/j.jvir.2008.09.034]
29. Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006; 23: 119-125 [PMID: 21326755 DOI: 10.1055/s-2006-941442]
30. Lee AJ, Gomes AS, Liu DM, Kee ST, Loh CT, McWilliams JP. The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy. Radiographics 2012; 32: 1121-1132 [PMID: 22786998 DOI: 10.1148/rg.324115114]
31. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7]
32. Chung WS, Lee KH, Park MS, Lee YJ, Kwon J, Baek SE, Kim MJ. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol 2012; 199: 349-359 [PMID: 22826396 DOI: 10.2214/AJR.11.7563]
33. Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Kulik L, Miller F, Yaghmai V, Murthy R, Larson A, Omary RA, Salem R. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008; 28: 81-99 [PMID: 18203932 DOI: 10.1148/rg.281065721]
34. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]
35. Zhu AX, Chabner BA, Tanabe KK. New trends and novel treatment for hepatocellular carcinoma: a global perspective. Oncologist 2010; 15 Suppl 4: 1-4 [PMID: 21115575 DOI: 10.1634/theoncologist.2010-S4-01]
36. Sacco R, Faggioni L, Bargellini I, Ginanni B, Battaglia V, Romano A, Bertini M, Bresci G, Bartolozzi C. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: Results of a pilot study. Dig Liver Dis 2013 Apr 8; Epub ahead of print [PMID: 23578581 DOI: 10.1016/j.dld.2013.03.004]
37. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Raptopoulos VD, Goldberg SN. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008; 191: 133-139 [PMID: 18562736 DOI: 10.2214/AJR.07.2848]
38. Goh V, Halligan S, Hugill JA, Bassett P, Bartram CI. Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. AJR Am J Roentgenol 2005; 185: 225-231 [PMID: 15972428]